Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

News SummaryMost relevantAll newsSector newsTweets

Hikma trims full year revenue forecast on Advair U.S. launch delay

share with twitter share with LinkedIn share with facebook
share via e-mail
05/19/2017 | 09:32am CEST

Drugmaker Hikma Pharmaceuticals Plc on Friday lowered its revenue forecast for the full year to reflect a delay in the launch of its generic asthma drug, after U.S. regulators denied approval citing "major" issues with the application.

Shares of the company fell as much 7.47 percent to 1,573 pence, the lowest since May, 2014. They were the top loser on the FTSE 100 bluechip index and the pan-European Stoxx 600 index.

Hikma now expects full-year revenue to be in the range of $2.0 billion-$2.1 billion at constant currency, down from its earlier forecast of $2.2 billion (1.7 billion pounds).

Earlier this month, the company said approval for its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair was unlikely in 2017.

Hikma and its partner Vectura Group Plc are in a race with Mylan to launch the first U.S. generic copy of Advair. The FDA has already delayed approval of Mylan's version.

Hikma on Friday lowered its 2017 revenue forecast for its generics business to $670 million, down from its earlier forecast of $800 million.

"This assumes we do not launch our generic version of Advair Diskus in 2017 and reflects the intensifying competitive environment in the U.S.," the company said in a statement.

Hikma maintained its full-year revenue estimate for its injectables unit at a range of $800 million-$825 million, with core operating margin seen in the high 30s.

(Reporting by Sanjeeban Sarkar and Tenzin Pema in Bengaluru; Editing by Sunil Nair)

share with twitter share with LinkedIn share with facebook
share via e-mail
09/21 GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc Provide New Data on Drug Deve..
09/21 GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc in the Area of Chemical Biol..
09/21 AGENUS : GSK's Shingrix containing Agenus' QS-21 Stimulon® adjuvant receives Una..
09/21 GLAXOSMITHKLINE : UK Trade Minister visits GSK Pakistan
09/21 GLAXOSMITHKLINE : 11% Potential Upside Indicated by Deutsche Bank
09/20 GLAXOSMITHKLINE : GSK's new triple lung drug beats other modern inhalers in stud..
09/20DJGLAXOSMITHKLINE : Announces Positive Results for Triple-Therapy Inhaler
09/20 GLAXOSMITHKLINE : Positive IMPACT results for Trelegy in COPD
09/20 GLAXOSMITHKLINE : GSK and Innoviva Report Positive Headline Results from IMPACT ..
09/19 GLAXOSMITHKLINE : FDA OKs Glaxo's inhaler, first one to combine 3 medicines
More news
News from SeekingAlpha
12:04p Hurricane Lessons
11:19a Alnylam And Sanofi Achieve An RNAi First
09/24 J&J : Thoughts On Sirukumab And Other Problems
09/21 FDA's Woodcock says clinical trials system "broken"
09/20 'Safer' Dividend Follower Favorites And Rogues Led By Capitala Finance
Financials ( GBP)
Sales 2017 30 232 M
EBIT 2017 8 500 M
Net income 2017 4 195 M
Debt 2017 14 079 M
Yield 2017 5,43%
P/E ratio 2017 19,13
P/E ratio 2018 15,41
EV / Sales 2017 2,86x
EV / Sales 2018 2,78x
Capitalization 72 499 M
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 17,2  GBP
Spread / Average Target 17%
EPS Revisions
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON14.36%352 651
NOVARTIS12.62%224 990
ROCHE HOLDING LTD.6.62%220 358
PFIZER10.75%214 146
MERCK AND COMPANY11.43%177 633